

## LIST OF FIGURES

Figure No.	Figure Title	Page No.
Figure 2.1.1	Top Spray Assembly	21
Figure 2.1.2	Bottom spray (Wurster) assembly	21
Figure 2.1.3	Tangential spray (Rotor pellet coating)	22
Figure 2.3.1	Different phases of Product Life Cycle	27
Figure 2.6.1	Star and centre points in face centred central composite design	40
Figure 2.7.1	Structural formula of Metoprolol Succinate	41
Figure 2.7.2	Structural formula of Metformin Hydrochloride	46
Figure 3.4.1	UV Absorption Spectrum of MS in (A) 0.1N HCl, (B) Phosphate buffer pH 3, (C) Phosphate buffer pH 6.8 and (D) Distilled water	67
Figure 3.4.2	Calibration Curves of MS in (A) 0.1N HCl, (B) Phosphate buffer pH 3, (C) Phosphate buffer pH 6.8 and (D) Distilled water	69
Figure 3.4.3	Calibration Curves of MS at 0 h and 24 h time points in (A) 0.1N HCl, (B) Phosphate buffer pH 3, (C) Phosphate buffer pH 6.8 and (D) Distilled water for stability study	71
Figure 3.4.4	Specificity and Interference Study Graph between MS and Excipients in (A) 0.1N HCl, (B) Phosphate buffer pH 3, (C) Phosphate buffer pH 6.8 and (D) Distilled water	75
Figure 3.4.5	Typical overlay plot of MS by HPLC	76
Figure 3.4.6	Calibration curve of MS by HPLC	77
Figure 3.4.7	Calibration Curves of MS at 0 h and 24 h time points for stability study by HPLC	78
Figure 3.4.8	UV Absorption Spectrum of MH in (A) 0.1N HCl, (B) Phosphate buffer pH 3, (C) Phosphate buffer pH 6.8 and (D) Distilled water	80
Figure 3.4.9	Calibration Curves of MH in (A) 0.1N HCl, (B) Phosphate buffer pH 6.8 and (C) Distilled water	82
Figure 3.4.10	Calibration Curves of MH at 0 h and 24 h time points in (A) 0.1N HCl, (B) Phosphate buffer pH 6.8 and (C) Distilled water for stability study	84
Figure 3.4.11	Specificity and Interference Study Graph between MH and	87

	Excipients in (A) 0.1N HCl, (B) Phosphate buffer pH 6.8, and (C) Distilled water	
Figure 3.4.12	Typical overlay plot of MH by HPLC	88
Figure 3.4.13	Calibration curve of MH by HPLC	89
Figure 3.4.14	Calibration Curves of MH at 0 h and 24 h time points for stability study by HPLC	90
Figure 4.3.1	Roadmap for process development	97
Figure 4.4.1	UV spectrum of Metoprolol succinate	138
Figure 4.4.2	UV spectrum of Metformin Hydrochloride	138
Figure 4.4.3	IR spectrum of Metoprolol succinate	139
Figure 4.4.4	IR spectrum of Metformin hydrochloride	139
Figure 4.4.5	DSC thermogram of Metoprolol succinate	141
Figure 4.4.6	DSC thermogram of Metformin hydrochloride	141
Figure 4.4.7	IR spectrum of Metoprolol succinate	144
Figure 4.4.8	IR spectrum of placebo blend	144
Figure 4.4.9	IR spectrum of Metoprolol succinate + placebo blend	145
Figure 4.4.10	IR spectrum of Metformin HCl	145
Figure 4.4.11	IR spectrum of placebo blend	146
Figure 4.4.12	IR spectrum of Metformin HCl + placebo blend	146
Figure 4.4.13	DSC thermogram of Metoprolol succinate and placebo blend	147
Figure 4.4.14	DSC thermogram of Metformin HCl and placebo blend	148
Figure 4.5.1	Cumulative drug released (%) Vs Time (h) for selection of core pellet size for MS MUPS	161
Figure 4.5.2	Cumulative drug released (%) Vs Time (h) for selection of core pellet size for MH MUPS	162
Figure 4.5.3	Cumulative drug released (%) Vs Time (h) for selection of core pellet quantity for MS MUPS	163
Figure 4.5.4	Cumulative drug released (%) Vs Time (h) for selection of core pellet quantity for MH MUPS	165
Figure 4.5.5	Selection of CR polymer for MS MUPS	166
Figure 4.5.6	Selection of CR polymer for MH MUPS	167
Figure 4.5.7	Schematic presentation of matrix-coated pellets and reservoir pellets	168

Figure 4.5.8	Reservoir and matrix techniques for MS loading	170
Figure 4.5.9	Reservoir and matrix techniques for MH loading	171
Figure 4.5.10	MS-CR coated pellet prepared by reservoir technique	172
Figure 4.5.11	MS-CR coated pellet prepared by matrix technique	172
Figure 4.5.12	MH-CR coated pellet prepared by reservoir technique	173
Figure 4.5.13	MH-CR coated pellet prepared by matrix technique	173
Figure 4.5.14	Optimization for extent of CR Coating and drug: polymer ratio - MS matrix system	176
Figure 4.5.15	Optimization of extent of CR coating and drug: polymer ratio -MH matrix system	178
Figure 4.5.16	Cumulative drug released Vs time for batches MS-36A, MS-36B and MS-36C at different curing time	179
Figure 4.5.17	Cumulative drug released Vs time for batch MH-30A, MH-30B and MH-30C at different curing time	180
Figure 4.5.18	Pictorial depiction of MS MUPS face centered central composite design	181
Figure 4.5.19	Pictorial depiction of MH MUPS face centered central composite design	182
Figure 4.5.20	Contour plot showing effect of $X_0$ and $X_1$ on responses Y1, Y2, Y3 and Y4 for MS MUPS	187
Figure 4.5.21	Contour plot showing effect of $X_0$ and $X_1$ on responses Y1, Y2, Y3 and Y4 for MH MUPS	189
Figure 4.5.22	Response surface plots showing effect of $X_0$ and $X_1$ on responses Y1, Y2, Y3 and Y4 for MS MUPS	191
Figure 4.5.23	Response surface plots showing effect of $X_0$ and $X_1$ on responses Y1, Y2, Y3 and Y4 for MH MUPS	192
Figure 4.5.24	Particle size distribution for MS Eudragit <sup>®</sup> E coated pellets	196
Figure 4.5.25	Particle size distribution for MH Eudragit <sup>®</sup> E coated pellets	197
Figure 4.5.26	Scanning electron microphotograph of MS Eudragit <sup>®</sup> E coated pellet	198
Figure 4.5.27	Scanning electron microphotograph of MH Eudragit <sup>®</sup> E coated pellet	198
Figure 4.5.28	Scanning electron microphotograph of transverse section of	199

	MS Eudragit <sup>®</sup> E coated pellet	
Figure 4.5.29	Scanning electron microphotograph of transverse section of MH Eudragit <sup>®</sup> E coated pellet	199
Figure 4.5.30	DSC thermogram of MS Eudragit <sup>®</sup> E coated pellet	200
Figure 4.5.31	DSC thermogram of MH Eudragit <sup>®</sup> E coated pellet	200
Figure 4.5.32	Cumulative drug released (%) Vs time from MS-Eudragit <sup>®</sup> E coated pellets	202
Figure 4.5.33	Cumulative drug released (%) Vs time from MH-Eudragit <sup>®</sup> E coated pellets	202
Figure 4.5.34	MS dissolution curve for zero order model	204
Figure 4.5.35	MS dissolution curve for first order model	204
Figure 4.5.36	MS dissolution curve for Higuchi model	205
Figure 4.5.37	MH dissolution curve for zero order model	205
Figure 4.5.38	MH dissolution curve for first order model	206
Figure 4.5.39	MH dissolution curve for Higuchi model	206
Figure 5.2.1	Schematic representation of CRPFR containing MUPS	210
Figure 5.3.1	Drug leaching study at different coating levels of Eudragit <sup>®</sup> E layer for MS CRPFR	219
Figure 5.3.2	Drug leaching study at different coating levels of Eudragit <sup>®</sup> E layer for MH CRPFR	220
Figure 5.5.1	Schematic representation of CRODT	229
Figure 5.6.1	Dissolution profile for Eudragit <sup>®</sup> E pellets and MS-CRODT	241
Figure 5.6.2	Dissolution profile for Eudragit <sup>®</sup> E pellets and MH-CRODT	242
Figure 5.6.3	Comparative dissolution profile for MS-Eudragit <sup>®</sup> E pellets and Batch MS-T9	246
Figure 5.6.4	Comparative dissolution profile for MS-Eudragit <sup>®</sup> E pellets, Batch MS-T10, MS -T11 and MS-T12	246
Figure 5.6.5	Comparative dissolution profile for MH-Eudragit <sup>®</sup> E pellets and Batch MH-T9	247
Figure 5.6.6	Comparative dissolution profile for MH-Eudragit <sup>®</sup> E pellets, Batch MH-T10, MH-T11 and MH-T12	247
Figure 5.6.7	SEM of transverse section of MS-CRODT (Batch MS-T11)	248
Figure 5.6.8	SEM of transverse section of MH-CRODT(Batch-MH- T12)	249

Figure 6.3.1	Plasma concentration profiles of orally administered MS formulations in rabbits	252
Figure 6.3.2	Plasma concentration profiles of orally administered MH formulations in rabbits	254